Glioblastoma Multiforme (GBM) is an aggressive primary brain tumor affecting mostly adults, with a median age at diagnosis of 55 years.
Current ‘standard-of-care’ treatment regimen typically consists of surgery to reduce the tumor mass to the extent safely feasible, followed by radiation therapy and chemotherapy.
At the direction of Bradmer Pharmaceuticals, the trial sponsor, the Phase III GLASS-ART Trial has been closed to further patient enrollment.
The company continues to support and track the progress of all patients currently enrolled in the GLASS-ART Trial.
For more information, please consult resources available at the company website, BradmerPharma.com, or send email to info@bradmerpharma.com.
Neuradiab® is an investigational drug currently in the clinical testing process established by the U.S. Food and Drug Administration (FDA) for the evaluation of new drugs.
The GLASS-ART Trial is a Phase III clinical trial testing Neuradiab®. The acronym GLASS-ART stands for:
GBM Locoregional Agent Survival Study -
Anti-tenascin Radiolabeled antibody Therapy.
The purpose of the GLASS-ART Trial is to determine if adding the study drug Neuradiab® to standard treatment regimen, which is composed of surgery followed by radiation and chemotherapy treatment, will be a better treatment than standard therapy alone.